business
Maxim Upgrades Gilead Sciences (GILD) to ‘Buy’
Key takeaways
- Maxim Upgrades Gilead Sciences (GILD) to ‘Buy’ Sultan Khalid Mon, May 25, 2026 at 12:26 AM GMT+7 2 min read GILD With an annual dividend yield of 2.50%, Gilead Sciences, Inc.
- (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
- On May 20, Maxim analyst Michael Okunewitch upgraded Gilead Sciences, Inc.
Maxim Upgrades Gilead Sciences (GILD) to ‘Buy’ Sultan Khalid Mon, May 25, 2026 at 12:26 AM GMT+7 2 min read GILD With an annual dividend yield of 2.50%, Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 12 Best Dividend Stocks to Invest in According to Hedge Funds.
Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
On May 20, Maxim analyst Michael Okunewitch upgraded Gilead Sciences, Inc. (NASDAQ:GILD) from ‘Hold’ to ‘Buy’, while assigning the stock a price target of $165. The price estimate reflects an upside of over 25% from the current levels.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop